Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 34 Show results per page	View Search Criteria \| Help With Results

Last Modified: 6/6/2007 First Published: 9/24/2003


1.		Phase III Randomized Study of Interferon alfa Versus CCI-779 Versus Interferon alfa and CCI-779 in Patients With Poor Prognosis Stage IV or Recurrent Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-0305091 WYETH-C-3066K1-304-WW, NCT00065468


2.		Study Evaluating Temsirolimus (CCI-779) in Mantle Cell Lymphoma (MCL)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				3066K1-305 NCT00117598

Last Modified: 12/21/2007 First Published: 8/1/2001


3.		Phase I/II Study of CCI-779 in Patients With Malignant Glioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				NCI				NABTC-0101 NCT00022724, NABTC-01-01

Last Modified: 12/3/2008 First Published: 5/23/2005


4.		Phase I/II Study of Erlotinib and Temsirolimus in Patients With Recurrent Malignant Glioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				NCI				NABTC-0402 NCI-06-C-0053, NABTC-04-02, NCT00112736

Last Modified: 5/1/2002 First Published: 3/1/2001


5.		Phase II Randomized Study of CCI-779 in Patients With Androgen-Independent Prostate Cancer (Summary Last Modified 05/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI, Pharmaceutical / Industry				UCLA-000606401 GENE-C9940-32, UCLA-CCI-779, W-AR-3066K1-201-US, NCI-G01-1917, NCT00012142

Last Modified: 8/25/2008 First Published: 5/1/2001


6.		Phase II Study of CCI-779 in Patients With Recurrent Glioblastoma Multiforme

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				NCCTG-N997B N997B, NCT00016328

Last Modified: 8/5/2008 First Published: 8/1/2001


7.		Phase II Study of CCI-779 in Patients With Metastatic Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				CHNMC-PHII-27 CHNMC-IRB-99167, NCI-29, NCT00022464, 29

Last Modified: 1/21/2008 First Published: 12/1/2001


8.		Phase II Randomized Study of CCI-779 in Patients With Extensive-Stage Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				ECOG-E1500 NCT00028028, E1500

Last Modified: 7/9/2008 First Published: 4/1/2002


9.		Phase II Study of CCI-779 in Patients With Previously Treated Mantle Cell Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				NCCTG-N0186 N0186, NCT00033267

Last Modified: 7/16/2004 First Published: 5/23/2003


10.		Phase II Randomized Study of Letrozole With or Without CCI-779 in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				CWRU-080234 CWRU-WAGM01102, WYETH-C-3066A1-204-WW, NCT00061971

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute